Clinical trials in Arezzo – page 10

1 011 clinical trials in Arezzo, Italy across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

Our site in ItalyStudi-Clinici.it

Arezzo at a glance

1 011

clinical trials

Research sites1

Quick filters

1 011 trials in Arezzo

Open in trial search

Juvenile idiopathic arthritis

Recruiting

A study to evaluate the safety and effectiveness of filgotinib in children and adolescents with juvenile idiopathic arthritis.

Registered drugNo placebo

A study to evaluate the safety and effectiveness of filgotinib in children and adolescents with juvenile idiopathic arthritis.

Registered drugNo placebo

Italy

Participants:0–17 years
Substances:Filgotinib
Sponsor:Alfasigma S.p.A.

Contact Research Centre

Non-small cell lung cancer

Recruiting

Comparing sotorasib and pembrolizumab with chemotherapy for patients with advanced non-small cell lung cancer and a KRAS G12C mutation

Registered drugNo placebo

Comparing sotorasib and pembrolizumab with chemotherapy for patients with advanced non-small cell lung cancer and a KRAS G12C mutation

Registered drugNo placebo

Italy

Participants:18–64 years · 65+ years
Substances:Calcium Folinate
Sponsor:Amgen Inc.

Contact Research Centre

Ovarian epithelial cancer

Recruiting

Comparing AZD5335 with mirvetuximab soravtansine or a drug combination in patients with platinum-resistant ovarian cancer

Registered drugNo placebo

Comparing AZD5335 with mirvetuximab soravtansine or a drug combination in patients with platinum-resistant ovarian cancer

Registered drugNo placebo

Italy

Participants:18–64 years · 65+ years
Substances:AZD5335
Sponsor:AstraZeneca AB

Contact Research Centre

Idiopathic pulmonary fibrosis

Recruiting

Study to evaluate the safety and effectiveness of inhaled nintedanib in patients with idiopathic pulmonary fibrosis

Investigational

Study to evaluate the safety and effectiveness of inhaled nintedanib in patients with idiopathic pulmonary fibrosis

Investigational

Italy

Participants:18–64 years · 65+ years
Substances:Nintedanib
Sponsor:Avalyn Pharma Inc.

Contact Research Centre

Squamous cell carcinoma of lung+4

Recruiting

A study of PF-08634404 and a drug combination in adults with advanced or metastatic non-small cell lung cancer

Registered drug

A study of PF-08634404 and a drug combination in adults with advanced or metastatic non-small cell lung cancer

Registered drug

Italy

Participants:18–64 years · 65+ years
Substances:Carboplatin
Sponsor:Pfizer Inc.

Contact Research Centre

Colorectal cancer metastatic

Recruiting

A Study Comparing PF-08634404 and a Drug Combination with Chemotherapy in Adults with Metastatic Colorectal Cancer

Registered drugNo placebo

A Study Comparing PF-08634404 and a Drug Combination with Chemotherapy in Adults with Metastatic Colorectal Cancer

Registered drugNo placebo

Italy

Participants:18–64 years · 65+ years
Substances:Bevacizumab
Sponsor:Pfizer Inc.

Contact Research Centre

Pericarditis

Recruiting

A study to evaluate the safety and effectiveness of KPL-387 in patients with well-controlled recurrent pericarditis

InvestigationalNo placebo

A study to evaluate the safety and effectiveness of KPL-387 in patients with well-controlled recurrent pericarditis

InvestigationalNo placebo

Italy

Participants:18–64 years · 65+ years
Substances:KPL-387
Sponsor:Kiniksa Pharmaceuticals GmbH

Contact Research Centre

Idiopathic pulmonary fibrosis

Recruiting

A study of the humanised IgG1 lalaps-yte monoclonal antibody against lysophosphatidic acid receptor 1 to treat adults with idiopathic pulmonary fibrosis

Investigational

A study of the humanised IgG1 lalaps-yte monoclonal antibody against lysophosphatidic acid receptor 1 to treat adults with idiopathic pulmonary fibrosis

Investigational

Italy

Participants:18–64 years · 65+ years
Substances:ABBV-142
Sponsor:AbbVie Deutschland GmbH & Co. KG

Contact Research Centre

Cardiac function disturbance postoperative+1

Recruiting

A study to evaluate the effectiveness of R2R01 in preventing acute kidney injury in patients at high risk following heart surgery.

Registered drug

A study to evaluate the effectiveness of R2R01 in preventing acute kidney injury in patients at high risk following heart surgery.

Registered drug

Italy

Participants:18–64 years · 65+ years
Substances:R2R01
Sponsor:River 2 Renal Corp.

Contact Research Centre

Non-small cell lung cancer

Recruiting

A study of MK-1084 and a drug combination for patients with advanced or metastatic non-small cell lung cancer with KRAS G12C mutations.

Registered drugNo placebo

A study of MK-1084 and a drug combination for patients with advanced or metastatic non-small cell lung cancer with KRAS G12C mutations.

Registered drugNo placebo

Italy

Participants:18–64 years · 65+ years
Substances:Cetuximab
Sponsor:Merck Sharp & Dohme LLC

Contact Research Centre

Pericarditis

Recruiting

A study to evaluate the safety and effectiveness of VTX2735 sodium in patients with recurrent pericarditis

InvestigationalNo placebo

A study to evaluate the safety and effectiveness of VTX2735 sodium in patients with recurrent pericarditis

InvestigationalNo placebo

Italy

Participants:65+ years
Substances:VTX2735 sodium
Sponsor:Zomagen Biosciences Limited

Contact Research Centre

Chronic kidney disease+1

Recruiting

A study to evaluate the effect of orforglipron on cardiovascular health in adults with atherosclerotic cardiovascular disease and/or chronic kidney disease

Investigational

A study to evaluate the effect of orforglipron on cardiovascular health in adults with atherosclerotic cardiovascular disease and/or chronic kidney disease

Investigational

Italy

Participants:18–64 years · 65+ years
Substances:Orforglipron hemicalcium
Sponsor:Eli Lilly & Co.

Contact Research Centre

Other cities in Italy

The busiest research cities in the country

All 230 cities in Italy

Clinical research in Arezzo

What the registry says about research in the country

01 Urological Oncology

Extensive research focusing on bladder cancer treatments, including innovative therapies combining immunotherapy with established treatments. Studies evaluate new approaches for both muscle-invasive and non-muscle invasive disease.

Bladder Cancer Immunotherapy
Urothelial Carcinoma Treatment
BCG Combination Therapies

Multiple trials exploring targeted treatments for patients with various stages of disease progression.

02 Prostate Cancer Research

Advanced studies examining new therapeutic approaches for metastatic prostate cancer, including novel drug combinations and targeted therapies for specific genetic mutations.

Castration-resistant Disease
Targeted Molecular Therapies
Hormone-based Treatments

Investigating innovative treatment sequences and combinations to improve patient outcomes.

03 Kidney Cancer Innovations

Cutting-edge research in renal cell carcinoma treatment, exploring immunotherapy combinations and targeted approaches for both early-stage and metastatic disease.

Immunotherapy Combinations
Targeted Molecular Agents
Advanced Disease Management

Focus on improving survival rates through novel therapeutic strategies.

Back to Italy All countries